These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16201181)

  • 21. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer.
    Ratliff TL; Kavoussi LR; Catalona WJ
    J Urol; 1988 Feb; 139(2):410-4. PubMed ID: 3276931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?
    Damiano R; De Sio M; Quarto G; Di Lorenzo G; Perdonà S; Palumbo IM; Azzarito G; Giugliano F; Autorino R
    BJU Int; 2009 Sep; 104(5):633-9. PubMed ID: 19298412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
    Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
    J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S; Akaza H; Isaka S; Kanetake H; Kubota Y; Kuroda M; Shinohara N; Shinka T; Tachibana M; Naito S; Hirao Y;
    Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
    Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R;
    Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of prophylactic intravesical instillation of BCG for superficial bladder cancer].
    Segawa N; Inamoto T; Nomi H; Ibuki N; Azuma H; Katsuoka Y
    Hinyokika Kiyo; 2009 Apr; 55(4):175-80. PubMed ID: 19462820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Internalization of Mycobacterium bovis, Bacillus Calmette Guerin, by bladder cancer cells is cytotoxic.
    Pook SH; Rahmat JN; Esuvaranathan K; Mahendran R
    Oncol Rep; 2007 Nov; 18(5):1315-20. PubMed ID: 17914591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction between bacteria and the lumenal bladder surface: modulation by pentosan polysulfate, an experimental and theoretical approach with clinical implication.
    Schamhart DH; de Boer EC; Kurth KH
    World J Urol; 1994; 12(1):27-37. PubMed ID: 7516779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
    Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
    Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacille Calmette-Guérin intravesical instillation and erectile function: is there a concern?
    Sighinolfi MC; Micali S; De Stefani S; Mofferdin A; Ferrari N; Giacometti M; Bianchi G
    Andrologia; 2007 Apr; 39(2):51-4. PubMed ID: 17430423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose instillation therapy with bacille Calmette-Guérin Tokyo 172 strain after transurethral resection: historical cohort study.
    Yoneyama T; Ohyama C; Imai A; Ishimura H; Hagisawa S; Iwabuchi I; Mori K; Kamimura N; Koie T; Yamato T; Suzuki T
    Urology; 2008 Jun; 71(6):1161-5. PubMed ID: 18279920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell proliferation and DNA content in rat urothelial lesions after repeat intravesical instillations of mitomycin C and bacillus Calmette-Guérin.
    Oliveira P; Palmeira C; Colaço A; De la Cruz P LF; Lopes C
    Urol Int; 2008; 80(1):90-7. PubMed ID: 18204241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer.
    Bisiaux A; Thiounn N; Timsit MO; Eladaoui A; Chang HH; Mapes J; Mogenet A; Bresson JL; Prié D; Béchet S; Baron C; Sadorge C; Thomas S; Albert EB; Albert PS; Albert ML
    J Urol; 2009 Apr; 181(4):1571-80. PubMed ID: 19230924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma.
    Agrawal MS; Agrawal M; Bansal S; Agarwal M; Lavania P; Goyal J
    Urology; 2007 Dec; 70(6):1075-8. PubMed ID: 18158020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.
    Hameed A; Sezian N; Thwaini A
    Can J Urol; 2007 Dec; 14(6):3745-9. PubMed ID: 18163926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.
    Gårdmark T; Jahnson S; Wahlquist R; Wijkström H; Malmström PU
    BJU Int; 2007 Apr; 99(4):817-20. PubMed ID: 17244282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.